Joan C.
- Country
- Spain
- Department
- Oncology
Research Overview
- Phase 1/2 Evaluation of EPI-7386 and Enzalutamide Combination Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
- Phase III Randomized Study of Cabazitaxel and Pelvic Radiotherapy in High-Risk Localized Prostate Cancer with Androgen Deprivation Therapy
- Efficacy and Safety of Capivasertib Plus Docetaxel in Metastatic Castration-Resistant Prostate Cancer: A Phase III Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 31 of 161 partner sites.
Specializations
Advanced Prostate Cancer Therapeutics
The investigator specializes in treating metastatic castration-resistant prostate cancer (mCRPC), exploring novel therapeutic combinations and treatment approaches.
- Hormone Therapy Integration
- Novel Anti-Androgen Treatments
- Targeted Radiation Therapies
Particular focus on developing treatment strategies for patients who have progressed on conventional hormonal therapies.
Combination Therapy Research
Expert in evaluating multi-modal treatment approaches combining different therapeutic agents to enhance treatment outcomes.
- Immunotherapy Combinations
- Targeted Therapy Protocols
- Hormone-Chemotherapy Integration
Specializes in investigating synergistic effects between various therapeutic agents in advanced prostate cancer.
Precision Medicine Applications
Focuses on personalized treatment approaches for different stages of prostate cancer progression.
- Biomarker-Driven Therapies
- Molecular Targeting Strategies
- Treatment Resistance Mechanisms
Emphasizes tailored therapeutic strategies based on individual patient characteristics and disease features.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.